The drug developer raised nearly $330m earlier this year according to its IPO filing, with $110m being supplied by SoftBank Vision Fund.
Telecommunications group SoftBank’s Vision Fund will get the chance to exit US-based infectious disease therapy developer Vir Biotechnology after the latter filed for a $100m initial public offering on Tuesday.
Vir is working on treatments for infectious diseases, having created four drug development platforms covering T cells, antibodies, innate immunity and small interfering ribonucleic acid (RNA) respectively.
The IPO proceeds will support ongoing phase 1/2 clinical trials for a prospective hepatitis B virus (HBV) treatment known as VIR-2218 and…
